Pure Global
NCT06318676

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

A Phase 1, Multi-center, Open-label, Single-dose Study to Assess the Pharmacokinetics of Mezigdomide (BMS-986348, CC-92480) in Adult Participants With Normal Renal Function, Severe Renal Impairment, and End-stage Renal Disease
Celgene·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Renal Impairment
Drug/Device/Intervention
Mezigdomide
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Celgene
Location
Miami Lakes,Orlando,Orlando, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Mar 15, 2024
End date
Mar 05, 2025
Enrollment
32 participants
Primary outcome

Maximum observed concentration (Cmax),Area under the plasma concentration-time curve (AUC),Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration (AUC(0-T))

Summary

The purpose of this study is to evaluate the drug levels of mezigdomide in participants with
 renal impairment.

ICD-10 classifications
Renal failureDisorders resulting from impaired renal tubular functionDisorder resulting from impaired renal tubular function, unspecifiedOther disorders resulting from impaired renal tubular functionAcute renal failure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06318676
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06318676 through Pure Global AI's free database. This Phase 1 trial is sponsored by Celgene and is currently Not yet recruiting. The study focuses on Renal Impairment. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.